NCT05206578Unknown3 期
To Evaluate the Efficacy and Safety of Combination Therapy of AGT and AGZ Versus Monotherapy of AGT in Patients With Primary Hypercholesterolemia
Ahn-Gook Pharmaceuticals Co.,Ltd1 个研究点 分布在 1 个国家目标入组 264 人开始时间: 2020年12月8日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 264
- 试验地点
- 1
- 主要终点
- % change in LDL-C level from baseline at Week 8
研究概览
简要总结
To Evaluate the Efficacy and Safety of Combination Therapy of AGT and AGZ Versus Monotherapy of AGT in Patients With Primary Hypercholesterolemia.
详细描述
A Multi-center, Randomized, Double-blinded, Active-controlled, Factorial Design Phase 3 Clinical Trial
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with primary hypercholesterolemia
排除标准
- •The subject not meet the specified LDL-C level
研究组 & 干预措施
AGT2, AGZ
Experimental
干预措施: AGT2, AGZ (Drug)
AGT2
Active Comparator
干预措施: AGT2 (Drug)
AGT4, AGZ
Experimental
干预措施: AGT4, AGZ (Drug)
AGT4
Active Comparator
干预措施: AGT4 (Drug)
结局指标
主要结局
% change in LDL-C level from baseline at Week 8
时间窗: Week 8
change in LDL-C level
次要结局
- Change in LDL-C level from baseline at Week 4(Week 4)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCTaGVHDNCT02677181Chinese PLA General Hospital100
Unknown
4 期
Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid MalignancyAcute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaNCT03873311Shenzhen Second People's Hospital114
已完成
不适用
A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) InfectionCytomegalovirus InfectionsHIV InfectionsNCT00000995National Institute of Allergy and Infectious Diseases (NIAID)60
Unknown
2 期
Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCTaGVHDcGVHDNCT05214066Chinese PLA General Hospital60
已完成
3 期
Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.dType 2 Diabetes MellitusNCT01787396LG Life Sciences433